Table of Contents Author Guidelines Submit a Manuscript
Analytical Cellular Pathology
Volume 2018 (2018), Article ID 9718585, 4 pages
Research Article

Liquid Biopsy in Rare Cancers: Lessons from Hemangiopericytoma

1Department of Molecular Medicine, Circulating Tumor Cells Unit, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy
2Policlinico Umerto I, II Division of Internal Medicine and Geriatrics, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy
3Department of Radiological, Oncological and Anatomopathological Sciences, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy
4Department of Movement, Human and Health Sciences, Division of Health Sciences, Foro Italico University of Rome, Piazza Lauro De Bosis 6, 00135 Rome, Italy
5Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, Sapienza University of Rome, Via Alfonso Borelli 50, 00161 Rome, Italy

Correspondence should be addressed to Walter Gianni

Received 11 January 2018; Accepted 8 February 2018; Published 7 March 2018

Academic Editor: Giovanni Tuccari

Copyright © 2018 Chiara Nicolazzo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Hemangiopericytoma (HPT) is a rare mesenchymal tumor of fibroblastic type and for its rarity is poorly studied. The most common sites of metastatic disease in patients with intracranial HPT are the bone, liver, and lung, suggestive for an hematogenous dissemination; for this reason, we investigated, for the first time, the presence of circulating tumor cells (CTCs) in hemangiopericytoma patient by CellSearch® and SceenCell® devices. Peripheral blood samples were drawn and processed by CellSearch, an EpCAM-dependent device, and ScreenCell®, a device size based. We found nontypical CTCs by CellSearch system and the immunofluorescence analysis performed on CTCs isolate by ScreenCell demonstrated the presence of single CTCs and CTC clusters. The molecular characterization of single CTCs and CTC clusters, using antibodies directed against EpCAM, CD34, cytokeratins (8, 18, and 19), and CD45, showed a great heterogeneity in CTC clusters. We believe that the present study may open a new scenario in the rare tumors: the introduction of the liquid biopsy and the molecular characterization of circulating tumor cells could lead to personalized targeted treatments and also for rare tumors.